Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. The Company has three clinical-stage drug candidates and several drug candidates in the preclinical and discovery stages. In December 2008, the Company entered into a partnership with Hoffmann-La Roche for its CRACM inhibitor program. The Company’s drug candidates include Elesclomol, STA-9090, STA-9584, Apilimod (STA-5326), Oral CRACM channel inhibitor and CRAC channel inhibitor. The Company has two clinical-stage programs and one preclinical-stage program in oncology.
(Source: 10-K) – less–ZoomInfo